21-Aug-2026
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 13-Aug 4:06 PM ET)
PRNewswire (Thu, 6-Aug 11:02 PM ET)
Globe Newswire (Tue, 4-Aug 5:43 PM ET)
Business Wire (Mon, 3-Aug 8:19 PM ET)
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
Business Wire (Sun, 2-Aug 5:27 PM ET)
PRNewswire (Fri, 31-Jul 11:22 AM ET)
PRNewswire (Thu, 30-Jul 10:01 AM ET)
Globe Newswire (Thu, 30-Jul 8:30 AM ET)
Globe Newswire (Wed, 29-Jul 10:55 AM ET)
Business Wire (Tue, 28-Jul 7:50 PM ET)
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity trades on the NASDAQ stock market under the symbol CELC.
As of August 21, 2026, CELC stock price climbed to $93.53 with 719,767 million shares trading.
CELC has a beta of 2.31, meaning it tends to be more sensitive to market movements. CELC has a correlation of 0.17 to the broad based SPY ETF.
CELC has a market cap of $4.58 billion. This is considered a Mid Cap stock.
Last quarter Celcuity reported $0 in Revenue and -$1.07 earnings per share. This fell short of revenue expectation by $-400,000 and exceeded earnings estimates by $.01.
In the last 3 years, CELC traded as high as $151.02 and as low as $7.58.
The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CELC has outperformed the market in the last year with a price return of +85.6% while the SPY ETF gained +21.7%. However, in the short term, CELC had mixed performance relative to the market. It has underperformed in the last 3 months, returning -34.4% vs +3.4% return in SPY. But in the last 2 weeks, CELC shares have fared better than the market returning +0.8% compared to SPY -1.0%.
CELC support price is $87.04 and resistance is $94.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.
